Sessions:
Suzhou
Thursday, September 3, 1pm – 5pm, Adocklab
Beijing
Tuesday, September 8, 1pm – 5pm, Yizhuang Biomedical Park
概述
Join this interactive workshop to explore how Model-Informed Drug Development (MIDD) approaches can accelerate decision-making across the drug development lifecycle — from early discovery to market access.
Through expert-led sessions and real-world case studies, participants will learn how modeling and simulation approaches, including QSP, PBPK, and Pharmacometrics, can support data-driven decision-making, optimize development strategies, and generate quantitative insights throughout the drug development process.
Benefits of the event
- Understand the role of MIDD in accelerating drug development and improving decision-making
- Explore real-world applications of QSP, PBPK, and Pharmacometrics across different therapeutic modalities
- Learn how modeling approaches support complex modalities, special populations, DDIs, and dose optimization
- Gain insights into quantitative strategies for regulatory submissions and market access in global markets
- Discover software solutions that enable scalable modeling and simulation workflows
点击报名
Caroline Mello
Portfolio Account Manager, CertaraCaroline is a Portfolio Account Manager at Certara specializing in modeling and simulation, including QSP, PBPK, and Pharmacometrics. She joined Certara via the acquisition of Applied BioMath, which focused on QSP for complex biologics. With a background in biochemistry and medicine, she is passionate about accelerating better therapeutics to patients through modeling and simulation.
宁佳，PhD
PBPK 高级顾问Jia Ning, PhD joined Certara’s Simcyp group in 2019. 主要负责药物PBPK模型的建立、药物间相互作用（DDIs）预测和特殊人群PK 的预测。
宁佳在 2015 - 2019 年于荷兰瓦格宁根大学进行研究，并擅长使用PBPK 模型预测药物的肝毒性以及预测比较物种间、人种间的差异。
Ruijuan Zhu
Software Solution Consultant, CertaraRuijuan graduated from East China Normal University and is a visiting scholar at the University of Houston, USA. She is an expert in bioinformatics, with rich working experience in disease detection and drug development. Currently, she is responsible for the consulting service for drug development-related software at Certara and possesses profound knowledge and experience in utilizing Pinnacle 21 Enterprise (P21E) to ensure data compliance with CDISC standards.
精选推荐
From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence.
